Funding for this research was provided by:
Norwegian Association of Asthma and Allergy
Received: 4 June 2019
Accepted: 30 November 2020
First Online: 9 December 2020
Ethics approval and consent to participate
: Informed written consent was obtained from all caregivers before inclusion. The study was approved by the Regional Committee for Medical and Health Research Ethics South East Norway (2014/2291).
: Not applicable.
: None of the authors have declared real or perceived conflict of interest for the present paper; however, the following have received honorary directly or indirectly: Eva Maria Rehbinder for presentations for Sanofi Genzyme, MEDA, Novartis and Perrigo. Astrid H Lossius for presentations for Sanofi Genzyme. Teresa Løvold Berents for presentation for MEDA, Novartis and Perrigo and as member of the advisory board of Sanofi Genzyme.